VSL#3 Co-Administration Is Associated with Altered Early-Phase Obeticholic Acid Exposure in MASLD Mice
Nutrients · 2026
DOI: 10.3390/nu18193296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2026. Verfasst von A-Hyeon Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nucleic Acid Therapies at the Department of Chemistry Institute for Chemical Epigenetics, Ludwig-Maximilians-Universität München, Butenand…. Hauptthemen laut MEDLINE: Chenodeoxycholic Acid, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hanyang University, Seoul ANCHOR Center, National Research Foundation of Korea.
Abstract (Originalsprache)
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and its global incidence continues to increase. MASLD can progress from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, effective preventive and therapeutic options remain limited. In this study, obeticholic acid (OCA) and the probiotic mixture VSL#3 were co-administered to a mouse model of MASLD to modulate gut microbiota and bile acid metabolism.
Methods
Male C57BL/6 mice were fed a WD to induce MASLD and treated with OCA, VSL#3, or both. Gut microbiota was analyzed by 16S rRNA sequencing, bile acid (BA) composition was assessed by LC–MS/MS, hepatic and intestinal gene expression was determined by quantitative real-time PCR (qPCR) and immunohistochemistry, and unconjugated OCA pharmacokinetics (PK) were evaluated.
Results
VSL#3-containing groups showed differences in selected taxa with reported bile salt hydrolase (BSH) potential and in BA composition, including a numerical shift toward higher levels of deconjugated BAs. Co-administration of OCA and VSL#3 was accompanied by lower hepatic steatosis, numerically favorable serum markers of liver injury, and lower cholesterol and total bilirubin levels. In addition, mice receiving VSL#3 showed numerically higher early plasma concentrations of unconjugated OCA. Lower intestinal ATP-binding cassette subfamily C member 2 (Abcc2) expression was also observed as a separate exploratory finding.
Conclusions
The co-administration of VSL#3 with OCA was accompanied by exploratory differences in selected biological parameters and early-phase unconjugated OCA exposure. Lower intestinal Abcc2/Mrp2 expression was observed as a separate exploratory finding, and no functional relationship between intestinal transporter expression and OCA pharmacokinetics was established.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Nucleic Acid Therapies at the Department of Chemistry Institute for Chemical Epigenetics, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377 München, Germany.
- Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea.
- Department of Translational Medicine, Graduate School of Biomedical Science & Engineering, Hanyang University, Seoul 04763, Republic of Korea.
- Pharmacomicrobiomics Research Center and College of Pharmacy, Hanyang University,Ansan 15588, Republic of Korea.
- Institute of Pharmaceutical Science and Technology and College of Pharmacy, Hanyang University, Ansan 15588, Republic of Korea.
- College of Pharmacy, Jeju National University, Jeju 63243, Republic of Korea.
ORCID-Profile: A-Hyeon Lee, Seung Min Lee, Hye Hyun Yoo, Jun Sang Yu, Hyun Sung Kim, Ji-Hee Shin, Dae Won Jun
Förderung
- Hanyang University
- Seoul ANCHOR Center
- National Research Foundation of Korea
Zitieren
APA
Lee, A. H., Lee, S. M., Kang, I. Y., Park, G. R., Yoo, H. H., Yu, J. S., Kim, H. S., Shin, J. H., Nam, Y. D., Yoon, E. L., & Jun, D. W. (2026). VSL#3 Co-Administration Is Associated with Altered Early-Phase Obeticholic Acid Exposure in MASLD Mice. Nutrients. https://doi.org/10.3390/nu18193296
Vancouver
Lee AH, Lee SM, Kang IY, Park GR, Yoo HH, Yu JS, et al. VSL#3 Co-Administration Is Associated with Altered Early-Phase Obeticholic Acid Exposure in MASLD Mice. Nutrients. 2026. doi:10.3390/nu18193296
BibTeX
@article{Lee2026,
author = {Lee, A-Hyeon and Lee, Seung Min and Kang, In Young and Park, Gye Ryeol and Yoo, Hye Hyun and Yu, Jun Sang and Kim, Hyun Sung and Shin, Ji-Hee and Nam, Young-Do and Yoon, Eileen Laurel and Jun, Dae Won},
title = {VSL#3 Co-Administration Is Associated with Altered Early-Phase Obeticholic Acid Exposure in MASLD Mice},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18193296}
}
EUVIMED